182923-55-3

Basic information

• Product Name: 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE
• Synonyms: 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE;2-Phenyl-5-trifluoromethyl-2H-pyrazol-3-amine;1-phenyl-3-(trifluoroMethyl)-1H-pyrazol-5-aMine;2-Phenyl-5-(trifluoromethyl)pyrazol-3-amine
• CAS NO: 182923-55-3
• Molecular Formula: C₁₀H₈F₃N₃
• Molecular Weight: 227.19
• Mol File: 182923-55-3.mol

Chemical Properties

• Melting Point: 101-102 °C(Solv: ethanol (64-17-5))
• Boiling Point: 323.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 0.39±0.10(Predicted)
• CAS DataBase Reference: 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE(182923-55-3)
• EPA Substance Registry System: 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE(182923-55-3)

Safety Data

• Hazardous Substances Data: 182923-55-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE is used as a building block for the synthesis of various biologically active molecules, contributing to the development of new pharmaceutical products. Its unique structure and properties make it a versatile chemical for creating compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical field, 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE is utilized as a key component in the synthesis of pesticides. Its potential as a building block allows for the creation of new and effective agricultural products, enhancing crop protection and management.
Overall, 2-PHENYL-5-TRIFLUOROMETHYL-2H-PYRAZOL-3-YLAMINE's applications in both the pharmaceutical and agrochemical industries highlight its importance as a versatile chemical compound with significant potential in chemical synthesis and the development of innovative products.

Upstream product

• 1093253-92-9 5-amino-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 110234-68-9 3-cyano-1,1,1-trifluoroacetone 
• 100-63-0 phenylhydrazine 

Downstream Products

• 1610051-04-1 1-(3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea 
• 1188909-35-4 phenyl (1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)carbamate 
• 1093253-95-2 N-methyl-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-amine 
• 1093253-97-4 N⁵-methyl-1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4,5-diamine 

Relevant articles and documents

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one

The multistep synthesis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one 15 has been carried out. The compound showed antiproliferative and apoptotic effects against K562, K562-R (imatinib mesilate resistant), HL60 and multidrug resistant (MDR) HL60 cell lines. Compound 15 showed a pro-apoptotic activity against HL60 and K562 resistant cell lines markedly higher than etoposide and busulfan, respectively. Flow cytometry studies carried out on K562 cells allowed to establish that 15 induces G0-G1 phase arrest followed by apoptosis.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.